OPPTS Series 870 Test Guidelines

OPPTS Number	Name	Existing Numbers			EPA Pub. no.
		OTS	OPP	OECD	712–C–
	Series 870—Health Effects Test Guidelines				
	Group A—Acute Toxicity Test Guidelines.				
870.1000	Acute toxicity testing–background	none	none	none	98–189
870.1100	Acute oral toxicity	798.1175	81–1	401, 420, 423, 425	98–190
870.1200	Acute dermal toxicity	798.1100	81–2	402	98–192
870.1300	Acute inhalation toxicity	798.1150	81–3	403	98–193
870.2400	Acute eye irritation	798.4500	81–4	405	98–195
870.2500	Acute dermal irritation	798.4470	81–5	404	98–196
870.2600	Skin sensitization	798.4100	81–6	406	98–197
	Group B—Subchronic Toxicity Test Guidelines.				
870.3050	Repeated dose 28–day oral toxicity study in rodents	none	none	407	99–366
870.3100	90-Day oral toxicity in rodents	798.2650	82–1	408	98–199
870.3150	90-Day oral toxicity in nonrodents	none	82–1	409	98–200
870.3200	21/28-Day dermal toxicity	none	82—2	410	98–201
870.3250	90-Day dermal toxicity	798.2250	82–3	411	98–202
870.3465	90-Day inhalation toxicity	798.2450	82–4	413	98–204
870.3550	Reproduction/development toxicity screening test	none	none	421	99–367
870.3650	Combined repeated dose toxicity with the reproduction/development toxicity screening test	none	none	422	99–368
870.3700	Prenatal developmental toxicity study	798.4900	83–3	414	98–207
870.3800	Reproduction and fertility effects	798.4700	83–4	416	98–208
	Group C—Chronic Toxicity Test Guidelines.				
870.4100	Chronic toxicity	798.3260	83–1	452	98–210
870.4200	Carcinogenicity	798.3300	83–2	451	98–211
870.4300	Combined chronic toxicity/carcinogenicity	798.3320	83–5	453	98–212
	Group D—Genetic Toxicity Test Guidelines.				
870.5100	Bacterial reverse mutation test	798.5100, .5265	84–2	471	98–247
870.5140	Gene mutation in *Aspergillus nidulans*	798.5140	84–2	none	98–215
870.5195	Mouse biochemical specific locus test	798.5195	84–2	none	98–216
870.5200	Mouse visible specific locus test	798.5200	84–2	none	98–217
870.5250	Gene mutation in *Neurospora crassa*	798.5250	84–2	none	98–218
870.5275	Sex-linked recessive lethal test in *Drosophila melanogaster*	798.5275	84–2	477	98–220
870.5300	In vitro mammalian cell gene mutation test	798.5300	84–2	476	98–221
870.5375	In vitro mammalian chromosome aberration test	798.5375	84–2	473	98–223
870.5380	Mammalian spermatogonial chromosomal aberration test	798.5380	84–2	483	98–224
870.5385	Mammalian bone marrow chromosomal aberration test	798.5385	84–2	475	98–225
870.5395	Mammalian erythrocyte micronucleus test	798.5395	84–2	474	98–226
870.5450	Rodent dominant lethal assay	798.5450	84–2	478	98–227
870.5460	Rodent heritable translocation assays	798.5460	84–2	485	98–228
870.5500	Bacterial DNA damage or repair tests	798.5500	84–2	none	98–229
870.5550	Unscheduled DNA synthesis in mammalian cells in culture	798.5550	84–2	482	98–230
870.5575	Mitotic gene conversion in *Saccharomyces cerevisiae*	798.5575	84–2	481	98–232
870.5900	In vitro sister chromatid exchange assay	798.5900	84–2	479	98–234
870.5915	In vivo sister chromatid exchange assay	798.5915	84–2	none	98–235
	Group E—Neurotoxicity Test Guidelines.				
870.6100	Acute and 28-day delayed neurotoxicity of organophosphorus substances	798.6450, .6540, .6560	81–7, 82–5, 82–6	418, 419	98–237
870.6200	Neurotoxicity screening battery	798.6050, .6200, .6400	81–8, 82–7, 83–1	424	98–238
870.6300	Developmental neurotoxicity study	none	83–6	none	98–239
870.6500	Schedule-controlled operant behavior	798.6500	85–5	none	98–240
870.6850	Peripheral nerve function	798.6850	85–6	none	98–241
870.6855	Neurophysiology: Sensory evoked potentials	798.6855	none	none	98–242
	Group F—Special Studies Test Guidelines.				
870.7200	Companion animal safety	none	none	none	98–349
870.7485	Metabolism and pharmacokinetics	798.7485	85–1	417	95–244
870.7600	Dermal penetration	none	85–3	none	98–350
870.7800	Immunotoxicity	none	85–7	none	98–351
	Group G—Health Effects Chemical-Specific Test Guidelines.				
870.8355	Combined chronic toxicity/carcinogenicity testing of respirable fibrous particles	798–3320	none	none	01–352